Bicara Therapeutics Inc. Common Stock (BCAX) - Total Assets
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) holds total assets worth $424.69 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BCAX net assets for net asset value and shareholders' equity analysis.
Bicara Therapeutics Inc. Common Stock - Total Assets Trend (2022–2024)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
Bicara Therapeutics Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Bicara Therapeutics Inc. Common Stock's total assets of $424.69 Million consist of 88.3% current assets and 11.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bicara Therapeutics Inc. Common Stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bicara Therapeutics Inc. Common Stock's current assets represent 88.3% of total assets in 2024, an increase from 74.4% in 2022.
- Cash Position: Cash and equivalents constituted 86.0% of total assets in 2024, up from 62.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Bicara Therapeutics Inc. Common Stock Competitors by Total Assets
Key competitors of Bicara Therapeutics Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Bicara Therapeutics Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.14 | 36.01 | 15.32 |
| Quick Ratio | 14.14 | 36.01 | 15.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $276.34 Million | $507.03 Million | $215.99 Million |
Bicara Therapeutics Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Bicara Therapeutics Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.17 |
| Latest Market Cap to Assets Ratio | 2.24 |
| Asset Growth Rate (YoY) | 143.3% |
| Total Assets | $569.20 Million |
| Market Capitalization | $1.28 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Bicara Therapeutics Inc. Common Stock's assets at a significant premium (2.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Bicara Therapeutics Inc. Common Stock's assets grew by 143.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bicara Therapeutics Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Bicara Therapeutics Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $569.20 Million | +143.26% |
| 2023-12-31 | $233.98 Million | +3390.71% |
| 2022-12-31 | $6.70 Million | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumor… Read more